This site is intended for healthcare professionals
News

CHMP issues positive opinion for 20-Valent Pneumococcal Conjugate Vaccine for the prevention of vaccine-type pneumococcal pneumonia in adults- Pfizer.

Read time: 1 mins
Last updated:20th Dec 2021
Published:18th Dec 2021
Pfizer Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion to recommend the granting of a marketing authorization for Pfizer’s Pneumococcal 20-valent Conjugate Vaccine (PCV 20), for the prevention of invasive disease and pneumonia caused by 20 Streptococcus pneumoniae (pneumococcus) serotypes in adults ages 18 years and older.

The CHMP’s positive opinion will now be reviewed for this indication by the European Commission (EC). The decision on whether to approve PCV20, whose European Union (EU) trade name will be Apexxnar, will be made by the EC and will be applicable to all 27 EU member states plus Iceland, Lichtenstein and Norway.

Condition: Pneumococcal Disease
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights